Clinical characteristics of selected patients in the multiple myeloma subcohort with available periengraftment samples from days +9 to +16
| Characteristic . | Myeloma subcohort (n = 99) . |
|---|---|
| Institution | |
| MSKCC | 65 (65.7) |
| Duke | 34 (34.3) |
| Mean age at auto-HCT, y (SD) | 60.9 (8.6) |
| Male sex | 56 (56.6) |
| Melphalan dose | |
| 200 mg/m2 | 74 (74.7) |
| 140 mg/m2 | 23 (23.2) |
| 180 mg | 1 (1.0) |
| 360 mg | 1 (1.0) |
| Status at transplant | |
| Complete response/near complete response | 15 (15.2) |
| Partial response | 32 (32.3) |
| Very good partial response | 48 (48.5) |
| Progressive disease or stable disease | 3 (3.0) |
| Other | 1 (1.0) |
| Median follow-up of survivors, mo (IQR) | 26.1 (16.4-36.6) |
| International Staging System* | |
| I | 50 (50.5) |
| II | 21 (21.2) |
| III | 19 (19.2) |
| Immunoglobulin | |
| IgG κ | 40 (40.4) |
| IgG λ | 23 (23.2) |
| IgA κ | 12 (12.1) |
| IgA λ | 4 (4.0) |
| κ free light chains | 7 (7.1) |
| λ free light chains | 3 (3.0) |
| Other† | 7 (7.1) |
| Cytogenetic risk‡ | |
| Standard | 52 (52.5) |
| High | 31 (31.3) |
| No. of previous lines of therapy | |
| 1 | 66 (66.7) |
| 2 | 22 (22.2) |
| ≥3 | 11 (11.1) |
| Characteristic . | Myeloma subcohort (n = 99) . |
|---|---|
| Institution | |
| MSKCC | 65 (65.7) |
| Duke | 34 (34.3) |
| Mean age at auto-HCT, y (SD) | 60.9 (8.6) |
| Male sex | 56 (56.6) |
| Melphalan dose | |
| 200 mg/m2 | 74 (74.7) |
| 140 mg/m2 | 23 (23.2) |
| 180 mg | 1 (1.0) |
| 360 mg | 1 (1.0) |
| Status at transplant | |
| Complete response/near complete response | 15 (15.2) |
| Partial response | 32 (32.3) |
| Very good partial response | 48 (48.5) |
| Progressive disease or stable disease | 3 (3.0) |
| Other | 1 (1.0) |
| Median follow-up of survivors, mo (IQR) | 26.1 (16.4-36.6) |
| International Staging System* | |
| I | 50 (50.5) |
| II | 21 (21.2) |
| III | 19 (19.2) |
| Immunoglobulin | |
| IgG κ | 40 (40.4) |
| IgG λ | 23 (23.2) |
| IgA κ | 12 (12.1) |
| IgA λ | 4 (4.0) |
| κ free light chains | 7 (7.1) |
| λ free light chains | 3 (3.0) |
| Other† | 7 (7.1) |
| Cytogenetic risk‡ | |
| Standard | 52 (52.5) |
| High | 31 (31.3) |
| No. of previous lines of therapy | |
| 1 | 66 (66.7) |
| 2 | 22 (22.2) |
| ≥3 | 11 (11.1) |